{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:32Z","timestamp":1788391172697,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.016","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"731-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tissue-Agnostic Cancer Therapy Approvals"],"prefix":"10.1016","volume":"40","author":[{"given":"Mohamed A.","family":"Gouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2026.05.016_bib1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s11523-023-00982-6","article-title":"FDA approvals of oncology drugs for tissue-agnostic indications","volume":"18","author":"Zettler","year":"2023","journal-title":"Target Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.016_bib2","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-23-0090","article-title":"Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications","volume":"29","author":"Gouda","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.016_bib3","unstructured":"RETEVMO\u00ae (selpercatinib) capsules, for oral use: FDA Packaging Insert."},{"key":"10.1016\/j.hoc.2026.05.016_bib4","series-title":"TAFINLAR\u00ae (dabrafenib) capsules, for oral use","year":"2022"},{"key":"10.1016\/j.hoc.2026.05.016_bib5","series-title":"MEKINIST\u00ae (trametinib) tablets, for oral use","year":"2022"},{"key":"10.1016\/j.hoc.2026.05.016_bib6","series-title":"KEYTRUDA\u00ae (pembrolizumab) injection, for intravenous use","year":"2022"},{"key":"10.1016\/j.hoc.2026.05.016_bib7","series-title":"JEMPERLI (dostarlimab-gxly) injection, for intravenous use","year":"2022"},{"key":"10.1016\/j.hoc.2026.05.016_bib8","series-title":"VITRAKVI\u00ae (larotrectinib) capsules, for oral use","year":"2022"},{"key":"10.1016\/j.hoc.2026.05.016_bib9","series-title":"ROZLYTREK (entrectinib) capsules, for oral use","year":"2022"},{"key":"10.1016\/j.hoc.2026.05.016_bib10","doi-asserted-by":"crossref","first-page":"100788","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision Oncology for BRAF Mutant Cancers with BRAF and MEK inhibitors: From Melanoma to Tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.hoc.2026.05.016_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"6892","key":"10.1016\/j.hoc.2026.05.016_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.016_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jop.13278","article-title":"Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: Systematic review and meta-analysis","volume":"51","author":"Martins-de-Barros","year":"2022","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.hoc.2026.05.016_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmolb.2020.00113","article-title":"The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape","volume":"7","author":"Vanni","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.016_bib15","first-page":"4661","article-title":"Comparison of diagnostic methods for the detection of a BRAF mutation in papillary thyroid cancer","volume":"17","author":"Zhao","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.hoc.2026.05.016_bib16","doi-asserted-by":"crossref","first-page":"e404770","DOI":"10.1200\/EDBK_404770","article-title":"Expanding the Benefit: Dabrafenib\/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors","volume":"43","author":"Gouda","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"33","key":"10.1016\/j.hoc.2026.05.016_bib17","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.016_bib18","article-title":"Dabrafenib plus trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results","volume":"38","author":"Geoerger","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.016_bib19","unstructured":"FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"key":"10.1016\/j.hoc.2026.05.016_bib20","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma","author":"Bouffet","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.016_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial","author":"Tian","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2026.05.016_bib22","series-title":"BRAFTOVI\u00ae (encorafenib) capsules, for oral use","year":"2022"},{"key":"10.1016\/j.hoc.2026.05.016_bib23","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/S0959-8049(16)33028-3","article-title":"The development of a potent, KDRNEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers","volume":"69","author":"Brandhuber","year":"2016","journal-title":"European Journal of Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.016_bib24","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.016_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4\u20135","key":"10.1016\/j.hoc.2026.05.016_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","article-title":"RET tyrosine kinase signaling in development and cancer","volume":"16","author":"Arighi","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"49","key":"10.1016\/j.hoc.2026.05.016_bib27","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1038\/sj.onc.1203857","article-title":"The RET proto-oncogene in human cancers","volume":"19","author":"Jhiang","year":"2000","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.016_bib28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"6461","key":"10.1016\/j.hoc.2026.05.016_bib29","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"issue":"6428","key":"10.1016\/j.hoc.2026.05.016_bib30","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.016_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.016_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"issue":"35","key":"10.1016\/j.hoc.2026.05.016_bib33","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.016_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12885-015-1146-8","article-title":"A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies","volume":"15","author":"Platt","year":"2015","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.016_bib35","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2014.36","article-title":"RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis","volume":"110","author":"Tsuta","year":"2014","journal-title":"Brit J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.016_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2013.07.009","article-title":"Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma","volume":"82","author":"Go","year":"2013","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.016_bib37","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","article-title":"The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics","volume":"11","author":"Cheng","year":"2016","journal-title":"J Thorac Oncol. Oct"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2026.05.016_bib38","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/modpathol.2008.10","article-title":"Thyroid carcinoma: molecular pathways and therapeutic targets","volume":"21","author":"Nikiforov","year":"2008","journal-title":"Mod Pathol. May"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.016_bib39","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/JTO.0000000000000135","article-title":"Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma","volume":"9","author":"Mizukami","year":"2014","journal-title":"J Thorac Oncol. May"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.016_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J Thorac Oncol. Jan"},{"key":"10.1016\/j.hoc.2026.05.016_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231177015","article-title":"Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers","volume":"15","author":"Gouda","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.hoc.2026.05.016_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.016_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.016_bib44","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II Trial","author":"Drilon","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.016_bib45","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.016_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101332","article-title":"Strategies for Mitigating Adverse Events Related to Selective RET Inhibitors in Patients with RET-altered Cancers","author":"Nardo","year":"2023","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/j.hoc.2026.05.016_bib47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol Therapeut"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.016_bib48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.016_bib49","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0298-184","article-title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.016_bib50","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.016_bib51","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.pathol.2023.05.002","article-title":"NTRK fusions in solid tumours: what every pathologist needs to know","volume":"55","author":"Nguyen","year":"2023","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.016_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.016_bib53","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.016_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First Global Approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.016_bib55","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.016_bib56","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamaoncol.2020.6371","article-title":"Tumor Mutation Burden and Cancer Treatment","volume":"7","author":"Fusco","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2026.05.016_bib57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","article-title":"Microsatellite instability: a review of what the oncologist should know","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.hoc.2026.05.016_bib58","article-title":"Landscape of Microsatellite Instability Across 39 Cancer Types","volume":"2017doi","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.016_bib59","doi-asserted-by":"crossref","first-page":"20495","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.hoc.2026.05.016_bib60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12935-019-0929-4","article-title":"Tumor mutation burden: from comprehensive mutational screening to the clinic","volume":"19","author":"Galuppini","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.016_bib61","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >\/=10: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.016_bib62","doi-asserted-by":"crossref","first-page":"12880","DOI":"10.1038\/s41598-021-91974-x","article-title":"Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer","volume":"11","author":"Dedeurwaerdere","year":"2021","journal-title":"Sci Rep-Uk"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.016_bib63","first-page":"13","article-title":"Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)","volume":"24","author":"Gilson","year":"2021","journal-title":"Cancers"},{"issue":"36","key":"10.1016\/j.hoc.2026.05.016_bib64","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.016_bib65","first-page":"11","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0","author":"Pavlick","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.016_bib66","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.016_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/biom12081031","article-title":"Dostarlimab: A Review","volume":"12","author":"Costa","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.hoc.2026.05.016_bib68","unstructured":"FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors."},{"issue":"25","key":"10.1016\/j.hoc.2026.05.016_bib69","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.016_bib70","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.016_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.016_bib72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2022.40.16_suppl.105","article-title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers","volume":"40","author":"Schram","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.016_bib73","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2022.40.16_suppl.3003","article-title":"First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation","volume":"40","author":"Dumbrava","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.016_bib74","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.hoc.2026.05.016_bib75","unstructured":"FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease."},{"key":"10.1016\/j.hoc.2026.05.016_bib76","unstructured":"FDA approves pemigatinib for relapsed or refractory myeloid\/lymphoid neoplasms with FGFR1 rearrangement."},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2026.05.016_bib77","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2021-148103","article-title":"A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid\/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.016_bib78","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.016_bib79","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14737140.2022.2069097","article-title":"What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?","volume":"22","author":"Bilusic","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.016_bib80","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High\/Deficient Mismatch Repair Solid Tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.016_bib81","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.2022.0506","article-title":"Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series","volume":"33","author":"Contrera","year":"2023","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.016_bib82","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/hed.26527","article-title":"Neoadjuvant selpercatinib for advanced medullary thyroid cancer","volume":"43","author":"Jozaghi","year":"2021","journal-title":"Head Neck"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.016_bib83","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.31701","article-title":"The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas","volume":"124","author":"DuBois","year":"2018","journal-title":"Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:00:39Z","timestamp":1788390039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000584"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.016","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue-Agnostic Cancer Therapy Approvals","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}